ACC at a glance

In the lead-up to ACC 2025, LucidQuest outlines the key trends shaping cardiology—from scientific advances to evolving diagnostics, treatment strategies, and AI applications.

📅 Build your schedule around the topics that interest you.

📥 Download the ACC 2025_Preview_by_LucidQuest

Key Topics From ACC 2025 Scientific Presentations

Ischemic Heart Diseases

  • Complete revascularization in MVD lowers MACE/CV death vs. culprit-only PCI.

  • DAPT reduces ischemic stroke but increases bleeding risk.

  • Beta-blockers in MI with preserved EF may lack benefits. 🩸

Pulmonary Vascular Disease

  • Mechanical thrombectomy tops thrombolysis in PE.

  • Treprostinil improves #PAH exercise capacity. 🫁

Valvular Disease

  • AS progresses faster in TTR-CA patients.

  • DOACs best warfarin for R-MVD + AF.

  • TAVR standardization lowers 1-year mortality. 💗🔎

Vascular Diseases

  • Hypertension control remains poor.

  • MANP aids resistant HTN (stronger in African Americans).

  • Pollution + short LTL = worse atherosclerosis. 🌐🩺

Cardiac Arrhythmias

  • Racial disparities in atrial flutter ablation outcomes.

  • Class IC outperforms class III in #NICM.

  • 4.2% of young female athletes flagged by ECG. 🏃‍♀️⚡

Heart Failure & Cardiomyopathies

  • ATTR-CM targeted therapies (vutrisiran, RNAi, SGLT2i) reduce mortality, enhance QoL, guiding new #HF management. 🏹💓

Cardiac Disease Prevention

  • SGLT2i + colchicine cut MACE.

  • Tirzepatide reduces CV risk.

  • Nebivolol/valsartan synergy helps HTN. 🎯💡

Congenital Heart Disease

  • Myosin inhibitors for HCM.

  • Down syndrome patients show similar long-term survival.

  • ASD closure fosters favorable remodeling. 🏥🔬

Special Topics

  • Novel HF strategies, TAVI updates, and bridging inequities in cardiac care. 📈🩺

Artificial Intelligence and Machine Learning at ACC 2025

AI in Screening

  • AI-ECG (AUROC ~0.94) flags HF, AF, HCM early. 🤖🔎

AI in Risk Stratification

  • XGBoost & LGBM predict mortality in AMI-CS/post-PCI (AUC up to 0.955). ⚙️📊

AI in HFpEF

  • EchoGo HF sees 50% risk for 27.9% preclinical patients. 🏹🌐

AI in Rare Disease

  • Tools like SynapsisAI find 29 ATTR-CM in 1 week, specificity ~96%. 🏆🧪

AI in Valve Disease

  • ML for TAVR sizing (AUC 0.85); DNN for RMV detection (AUC 0.877). ⛑️🔬

AI for Population Health

  • Smartwatch AF detection = 1.6× MACE risk; AI-based CAC scoring finds unaddressed high-risk patients. 📲💗

AI in Pediatric and Global Health

  • AI > standard ECG in WPW (AUROC 0.99); global RHD detection (AUC 0.89). 🌎🌱

AI Workflow

  • ePRISM halves LOS post-PCI; NNM predicts same-day LAAC discharge (AUC 0.80). 🤝

Imaging AI

  • ML multiparametric CMR (macro-AUC 0.90) for CAV staging; DTI-CMR + U-Net (Dice = 0.85) for arrhythmic imaging. 🏹💥

AI for Biomarker Personalization

  • AI identifies tirzepatide responders; AI gait detects subclinical frailty. 🩺

Clinician Perceptions on AI

  • 64–75% lack ML knowledge, yet 75% see patient benefits—education gap remains. 📚⚖️

 

📅 Build your schedule around the topics that interest you.

📥 Download the ACC 2025_Preview_by_LucidQuest

Contact us for end-to-end conference coverage.

Privacy Preference Center